Cargando…
Progression after First-Line Cyclin-Dependent Kinase 4/6 Inhibitor Treatment: Analysis of Molecular Mechanisms and Clinical Data
Cyclin-dependent kinase 4/6 inhibitors (CDK4/6iss) are widely used in first-line metastatic breast cancer. For patients with progression under CDK4/6is, there is currently no standard treatment recommended at the category 1 level in international guidelines. The purpose of this article is to review...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10572355/ https://www.ncbi.nlm.nih.gov/pubmed/37833875 http://dx.doi.org/10.3390/ijms241914427 |
_version_ | 1785120215683563520 |
---|---|
author | Villa, Federica Crippa, Alessandra Pelizzoni, Davide Ardizzoia, Alessandra Scartabellati, Giulia Corbetta, Cristina Cipriani, Eleonora Lavitrano, Marialuisa Ardizzoia, Antonio |
author_facet | Villa, Federica Crippa, Alessandra Pelizzoni, Davide Ardizzoia, Alessandra Scartabellati, Giulia Corbetta, Cristina Cipriani, Eleonora Lavitrano, Marialuisa Ardizzoia, Antonio |
author_sort | Villa, Federica |
collection | PubMed |
description | Cyclin-dependent kinase 4/6 inhibitors (CDK4/6iss) are widely used in first-line metastatic breast cancer. For patients with progression under CDK4/6is, there is currently no standard treatment recommended at the category 1 level in international guidelines. The purpose of this article is to review the cellular mechanisms underlying the resistance to CDK4/6is, as well as treatment strategies and the clinical data about the efficacy of subsequent treatments after CDK4/6is-based therapy. In the first part, this review mainly discusses cell-cycle-specific and cell-cycle-non-specific resistance to CDK4/6is, with a focus on early and late progression. In the second part, this review analyzes potential therapeutic approaches and the available clinical data on them: switching to other CDK4/6is, to another single hormonal therapy, to other target therapies (PI3K, mTOR and AKT) and to chemotherapy. |
format | Online Article Text |
id | pubmed-10572355 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-105723552023-10-14 Progression after First-Line Cyclin-Dependent Kinase 4/6 Inhibitor Treatment: Analysis of Molecular Mechanisms and Clinical Data Villa, Federica Crippa, Alessandra Pelizzoni, Davide Ardizzoia, Alessandra Scartabellati, Giulia Corbetta, Cristina Cipriani, Eleonora Lavitrano, Marialuisa Ardizzoia, Antonio Int J Mol Sci Review Cyclin-dependent kinase 4/6 inhibitors (CDK4/6iss) are widely used in first-line metastatic breast cancer. For patients with progression under CDK4/6is, there is currently no standard treatment recommended at the category 1 level in international guidelines. The purpose of this article is to review the cellular mechanisms underlying the resistance to CDK4/6is, as well as treatment strategies and the clinical data about the efficacy of subsequent treatments after CDK4/6is-based therapy. In the first part, this review mainly discusses cell-cycle-specific and cell-cycle-non-specific resistance to CDK4/6is, with a focus on early and late progression. In the second part, this review analyzes potential therapeutic approaches and the available clinical data on them: switching to other CDK4/6is, to another single hormonal therapy, to other target therapies (PI3K, mTOR and AKT) and to chemotherapy. MDPI 2023-09-22 /pmc/articles/PMC10572355/ /pubmed/37833875 http://dx.doi.org/10.3390/ijms241914427 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Villa, Federica Crippa, Alessandra Pelizzoni, Davide Ardizzoia, Alessandra Scartabellati, Giulia Corbetta, Cristina Cipriani, Eleonora Lavitrano, Marialuisa Ardizzoia, Antonio Progression after First-Line Cyclin-Dependent Kinase 4/6 Inhibitor Treatment: Analysis of Molecular Mechanisms and Clinical Data |
title | Progression after First-Line Cyclin-Dependent Kinase 4/6 Inhibitor Treatment: Analysis of Molecular Mechanisms and Clinical Data |
title_full | Progression after First-Line Cyclin-Dependent Kinase 4/6 Inhibitor Treatment: Analysis of Molecular Mechanisms and Clinical Data |
title_fullStr | Progression after First-Line Cyclin-Dependent Kinase 4/6 Inhibitor Treatment: Analysis of Molecular Mechanisms and Clinical Data |
title_full_unstemmed | Progression after First-Line Cyclin-Dependent Kinase 4/6 Inhibitor Treatment: Analysis of Molecular Mechanisms and Clinical Data |
title_short | Progression after First-Line Cyclin-Dependent Kinase 4/6 Inhibitor Treatment: Analysis of Molecular Mechanisms and Clinical Data |
title_sort | progression after first-line cyclin-dependent kinase 4/6 inhibitor treatment: analysis of molecular mechanisms and clinical data |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10572355/ https://www.ncbi.nlm.nih.gov/pubmed/37833875 http://dx.doi.org/10.3390/ijms241914427 |
work_keys_str_mv | AT villafederica progressionafterfirstlinecyclindependentkinase46inhibitortreatmentanalysisofmolecularmechanismsandclinicaldata AT crippaalessandra progressionafterfirstlinecyclindependentkinase46inhibitortreatmentanalysisofmolecularmechanismsandclinicaldata AT pelizzonidavide progressionafterfirstlinecyclindependentkinase46inhibitortreatmentanalysisofmolecularmechanismsandclinicaldata AT ardizzoiaalessandra progressionafterfirstlinecyclindependentkinase46inhibitortreatmentanalysisofmolecularmechanismsandclinicaldata AT scartabellatigiulia progressionafterfirstlinecyclindependentkinase46inhibitortreatmentanalysisofmolecularmechanismsandclinicaldata AT corbettacristina progressionafterfirstlinecyclindependentkinase46inhibitortreatmentanalysisofmolecularmechanismsandclinicaldata AT ciprianieleonora progressionafterfirstlinecyclindependentkinase46inhibitortreatmentanalysisofmolecularmechanismsandclinicaldata AT lavitranomarialuisa progressionafterfirstlinecyclindependentkinase46inhibitortreatmentanalysisofmolecularmechanismsandclinicaldata AT ardizzoiaantonio progressionafterfirstlinecyclindependentkinase46inhibitortreatmentanalysisofmolecularmechanismsandclinicaldata |